Impaired fasting glucose as a risk factor for atherothrombotic or lacunar cerebral infarction. A case-control study;La glucemia basal alterada es un factor de riesgo para el infarto cerebral aterotrombótico o lacunar. Estudio de casos y controles

Neurologia

Volumn 24, Issue 1, 2009, Pages 24-29

  Baena Diez, J M ^a,c   Arboix, A ^b   Merino Audi, M ^a   Tomas Pelegrina, F ^a   EHacuria Torres, ^a   Garcia Lareo, M ^a   Liste Salvador, V ^a  

^a Áreas Básicas de Salud La Marina y Dr Carles Ribas   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Centre d'Atenció Primària Baix A Mar Consell Comarcal Del Garraf Vilanova i la Geltrú   (Spain)

Author keywords

Atherothrombotic infarction; Cerebrovascular accident; Diabetes mellitus; Impaired fasting glucose; Lacunar infarction

Indexed keywords

CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROTHROMBOSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEALTH SERVICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION BASED CASE CONTROL STUDY; RANDOM SAMPLE; SMOKING; THROMBOSIS; URBAN AREA;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BRAIN INFARCTION; CASE-CONTROL STUDIES; EMBOLISM, CHOLESTEROL; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDIABETIC STATE; RISK FACTORS;

EID: 63449099830     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick FB, Hademenos G, et al. Primary prevention of ischemic stroke. A statment for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001;32:280-99.
2. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a firsr stroke. A review of guidelines and a multi- disciplinary consensus statement from the National Stroke Association. JAMA 1999;281:1112-20.
3. Helgason CM, Wolf PH. American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke. Introduction. Stroke 1997;28:1498-500.
4. Arboix A, Sánchez E, Balcells M. Factores de riesgo en la enfermedad cere- brovascular aguda: estudio comparativo entre el infarto y la hemorragia en 1.702 pacientes. Med Clin (Barc) 2001; 116:89-91.
5. Arboix A, Morcilllo C, Garcia-Eroles C, Oliveres M, Massons J, Targa C. Different vascular risk factor profiles in ischemic stroke subtypes: a study from the Sagrat Cor Hospital of Barcelona Stroke Registry. Acta Neurol Scand 2000;102:264-70.
6. Bloomgarden ZT. Cardiovascular disease in type 2 diabetes. Diabetes Care 1999;22:1739-44.
7. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and manegement. JAMA 2002; 287:2570-81.
8. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framing- ham Study. JAMA 1979;241:2035-8.
9. Baena JM, Oller M, Martin R, Nicolau M, Altes A, Iglesias C. Impacto de los nuevos criterios diagnósticos propuestos por la Asociación Americana de Diabetes (ADA-97) sobre la prevalencia diagnóstica de diabetes mellitus tipo 2. Aten Prim 1999;24:97-100.
10. The Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Report of the Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-97.
11. Keen H. Impact of the new criteria for diabetes on pattern of disease. Lancet 1998;352:1000-1.
12. Alberti KGMM, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of WHO consultation. Diabetes Med 1998; 15:539-53.
13. Stamler J, Vaccaro, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Reseach Group. Diabetes, other risk factors and 12 years cardiovascular mortality for men screening in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
14. De Marco R, Locatelli F, Zoppini G, Verlatto G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-61.
15. Arboix A, Álvarez-Sabin J, Soler L, for the Cerebrovascular Study Group of the Spanish Society of Neurology. Nomenclatura de las enfermedades vas- culares cerebrales. Neurologia 1998;(Suppl. 1):1-10.
16. Córdoba García R, Ortega Sánchez-Pinilla R, Cabezas Peña C, Forés Garcia D, Nebot Adell M. Recomendaciones sobre el estilo de vida. Aten Prim 1999;24(Suppl. 1):118-32.
17. Programa de Actividades Preventivas y de Promoción de la Salud. Guia de Prevención Cardiovascular. Madrid: Sociedad Española de Medicina Familiar y Comunitaria, 1996.
18. Programas básicos de salud. Diabetes Mellitus. Sociedad Española de Medicina Familiar y Comunitaria. Madrid: Doyma, 1998.
19. Whittermore A. Sample size for logistic regression with small response probability. J Am Statist Assn 1981;76:27-32.
20. Ellacuria A, Baena JM, Garcia M, Parra LL, Merino M, Liste V. Risk factors for non-embolic stroke in general population: a case-control study in mediterranean country. En: Book of abstracts. The 2002 Conference of the European Society of General Practice/Family Medicine WONCA Region Europe. London, p. 70.
21. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction. A case-control study. J Am Coll Cardiol 1999;33:612-9.
22. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Maldelzweig L, Behar S. Impaired fasting glucose concentrations in nondiabetic patiens with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001;141:485-90.
23. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000;86:897-902.
24. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999;22: 920-4.
25. Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol 2001;88(Suppl.):16H-9.
26. Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, et al. Incidence and risk factors for subtypes of crebral infarction in a general population: the Hisayama study. Stroke 2000;31:261 6-22.
27. Qureshi AI, Giles WH, Croft JB. Impaired glucose intolerance and the likelihood of nonfatal stroke and myocardial infarction: the Third National Health and Nutrition Examination Survey. Stroke 1998;29:1329-32.
28. Liu J, Grundy SM, Wang W, Smith SC, Vega GL, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007;153:552-8.
29. Kaarisalo MM, Jaiha I, Arve S, Lehtonen A. Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years. Age Ageing 2006;35:592-6.
30. Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004;35:2351-5.
31. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovacular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed 12.4 years. Diabetes Care 1999;22:233-40.
32. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 1999;22:659-60.
33. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999;22:696-9.
34. 34.Haffner S. The importance of hyperglicemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998;19:583-92.
35. Henry P, Thomas F, benetos A, Guize L. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002;40:458-63.
36. Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, et al. Prospective association of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 1999;22:1077-83.
37. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
38. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP- NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
39. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
40. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low dose aspirin on patiens with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
41. Haffner SM, Alexander CM, Cook TJ, Bocuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patiens with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159: 2661-7.
42. Smith DG, Clemens J, Crede W, Harvey M, Gracely EJ. Impact of multiple comparisons in randomized clinical trials. Am J Med 1987;83:545-50.
43. Baena Diez JM, Martinez Martinez JL, Álvarez Perez B, Tomàs Pelegrina J, Piñol Forcadell P, Raidó Quintana EM, et al. Riesgo cardiovascular asocia- do a las nuevas categorías diagnósticas de la diabetes mellitus propuestas por la Asociación Americana de Diabetes. Aten Prim 2001;28:31-8.
44. Baena Díez JM, González Tejón I, Pomares Sajkiewick M, Rovira España M, Martínez Martínez JL, Tomás Pelegrina J. Episodios cardiovasculares asocia- dos a las nuevas categorias diagnósticas de la diabetes mellitus propuestas por la Asociación Americana de Diabetes. Aten Prim 2002;29:343-7.
45. Fuentes EM, de la Poza M, Hidalgo A, Hernández MR, Vila M, Baena JM, et al. Primary prevention of major cardiovascular events. Could they have been prevented with a better coverage of preventive activities? Case-control study. En: Libro de resúmenes de la First European Network Organisations Open Conference WONCA '99. Palma de Mallorca, 1999; p. 104.